TECHLAB Inc. announced that it received U.S. Food and Drug Administration clearance for E. HISTOLYTICA QUIK CHEK test. E. HISTOLYTICA QUIK CHEK test is the only rapid diagnostic test that specifically detects pathogenic E. histolytica and does not cross react with non-pathogenic Entamoeba dispar. E. HISTOLYTICA QUIK CHEK test can be paired with the GIARDIA/CRYPTOSPORIDIUM QUIK CHEK test to provide a complete triple parasite screen. E. histolytica is an intestinal parasite which infects an estimated 50 million people each year. Infected individuals may develop amebiasis, characterized by bloody diarrhea, colitis, and liver abscesses. The disease is fatal in up to 100,000 cases annually, and has been diagnosed in 12% of travelers returning from the developing world with acute diarrhea1,2,3. E. histolytica is morphologically identical to a non-pathogenic species, E. dispar, making accurate diagnosis very difficult. Other currently available tests and microscopy cannot differentiate between the two species, frequently resulting in an inaccurate diagnosis. The E. HISTOLYTICA QUIK CHEK test is a rapid assay for the qualitative detection of E. histolytica in fecal samples. It targets an adhesin protein unique to E. histolytica. The test can be used for quick and reliable diagnosis of amebiasis. Together with the GIARDIA/CRYPTOSPORIDIUM QUIK CHEK test, E. HISTOLYTICA QUIK CHEK test provides a rapid diagnostic screening tool for common intestinal parasites.